CTSO insider transaction filings
Cytosorbents Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen CTSO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 4 filings by 3 insiders — 208,347 shares, $120,435 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 200,000 shares @ $0.35 ($70,000) by Chan Phillip P., filed 2026-09-09.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Chan Phillip P. — Chief Executive Officer, Director | 2 | 2 legs · 203,774 sh · $92,644 | — | — |
| Sobel Alan D. — Director | 1 | 3 legs · 2,500 sh · $15,254 | — | — |
| Capponi Vincent — President and COO | 1 | 2 legs · 2,073 sh · $12,537 | — | — |
Recent Form 4 filings — Cytosorbents Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Purchase (P): 3,774 @ $6 | EDGAR |
| 2026-09-16 | 4 | Sobel Alan D. — Director | Purchase (P): 1,900 @ $6.12 · Purchase (P): 500 @ $6.05 · Purchase (P): 100 @ $6.01 | EDGAR |
| 2026-09-16 | 4 | Capponi Vincent — President and COO | Purchase (P): 1,800 @ $6.07 · Purchase (P): 273 @ $5.90 | EDGAR |
| 2026-09-09 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Purchase (P): 200,000 @ $0.35 | EDGAR |
| 2026-06-16 | 4 | MARIANI PETER J — Chief Financial Officer | Purchase (P): 100,000 @ $0.44 | EDGAR |
| 2026-06-15 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Purchase (P): 251,136 @ $0.40 · Purchase (P): 10,333 @ $0.43 | EDGAR |
| 2025-11-20 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Grant/award (A): 100,000 @ $0.64 | EDGAR |
| 2025-08-08 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Grant/award (A): 105,600 @ $0 · Grant/award (A): 136,400 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Jones Edward Raymond — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | BATOR MICHAEL G. — Director | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | MARIANI PETER J — Chief Financial Officer | Grant/award (A): 71,500 @ $0 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Kim Jiny — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Capponi Vincent — President and COO | Grant/award (A): 89,100 @ $0 · Grant/award (A): 111,100 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Deliargyris Efthymios — Chief Medical Officer | Grant/award (A): 70,000 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Sobel Alan D. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | BATOR MICHAEL G. — Director | Code (O): 10,000 @ $1.13 · Code (O): 15,879 (derivative) @ $1.13 | EDGAR |
| 2025-02-26 | 4 | Capponi Vincent — President and COO | Code (O): 12,000 @ $1.13 · Code (O): 12,000 (derivative) @ $1.13 | EDGAR |
| 2025-02-26 | 4 | MARIANI PETER J — Chief Financial Officer | Code (O): 32,625 @ $1.13 · Code (O): 32,625 (derivative) @ $1.13 | EDGAR |
| 2025-02-26 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Code (O): 34,168 @ $1.13 · Code (O): 34,168 (derivative) @ $1.13 | EDGAR |
| 2025-02-26 | 4 | Sobel Alan D. — Director | Code (O): 21,950 @ $1.13 · Code (O): 21,950 (derivative) @ $1.13 | EDGAR |
| 2025-01-22 | 4 | BATOR MICHAEL G. — Director | Option exercise/expiry (X): 15,879 @ $1 · Option exercise/expiry (X): 15,879 (derivative) @ $0 · Other (J): 15,879 (derivative) · Other (J): 15,879 (derivative) | EDGAR |
| 2025-01-22 | 4 | Capponi Vincent — President and COO | Option exercise/expiry (X): 31,760 @ $1 · Option exercise/expiry (X): 31,760 (derivative) @ $0 · Other (J): 31,760 (derivative) · Other (J): 31,760 (derivative) | EDGAR |
| 2025-01-22 | 4 | Deliargyris Efthymios — Chief Medical Officer | Option exercise/expiry (X): 16,233 @ $1 · Option exercise/expiry (X): 16,233 (derivative) @ $0 · Other (J): 16,233 (derivative) · Other (J): 16,233 (derivative) | EDGAR |
| 2025-01-22 | 4 | Sobel Alan D. — Director | Option exercise/expiry (X): 21,950 @ $1 · Option exercise/expiry (X): 21,950 (derivative) @ $0 · Other (J): 21,950 (derivative) · Other (J): 21,950 (derivative) | EDGAR |
| 2025-01-22 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Option exercise/expiry (X): 90,832 @ $1 · Option exercise/expiry (X): 90,832 (derivative) @ $0 · Other (J): 90,832 (derivative) · Other (J): 90,832 (derivative) | EDGAR |
| 2025-01-22 | 4 | MARIANI PETER J — Chief Financial Officer | Option exercise/expiry (X): 32,625 @ $1 · Option exercise/expiry (X): 32,625 (derivative) @ $0 · Other (J): 32,625 (derivative) · Other (J): 32,625 (derivative) | EDGAR |
| 2024-12-16 | 4 | MARIANI PETER J — Chief Financial Officer | Purchase (P): 20,000 @ $0.96 | EDGAR |
| 2024-12-13 | 4 | MARIANI PETER J — Chief Financial Officer | Purchase (P): 11,363 @ $0.89 · Purchase (P): 20,000 @ $0.89 | EDGAR |
| 2024-10-08 | 4 | Deliargyris Efthymios — Chief Medical Officer | Grant/award (A): 100,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-10-08 | 4 | Capponi Vincent — President and COO | Grant/award (A): 100,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-08-16 | 4 | MARIANI PETER J — Chief Financial Officer | Grant/award (A): 110,000 @ $0 · Grant/award (A): 65,000 @ $0 · Grant/award (A): 175,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Jones Edward Raymond — Director | Grant/award (A): 22,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | Deliargyris Efthymios — Chief Medical Officer | Grant/award (A): 61,000 @ $0 · Grant/award (A): 86,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | Sobel Alan D. — Director | Grant/award (A): 22,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | BLOCH KATHLEEN P. — Chief Financial Officer | Grant/award (A): 65,000 @ $0 · Grant/award (A): 87,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | BATOR MICHAEL G. — Director | Grant/award (A): 44,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | Capponi Vincent — President and COO | Grant/award (A): 81,000 @ $0 · Grant/award (A): 101,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | Kim Jiny — Director | Grant/award (A): 22,000 (derivative) | EDGAR |
| 2024-04-04 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Grant/award (A): 96,000 @ $0 · Grant/award (A): 124,000 (derivative) | EDGAR |
| 2024-04-02 | 4 | Deliargyris Efthymios — Chief Medical Officer | Grant/award (A): 47,088 (derivative) | EDGAR |
| 2024-04-02 | 4 | Capponi Vincent — President and COO | Grant/award (A): 48,923 (derivative) | EDGAR |
| 2024-04-02 | 4 | BLOCH KATHLEEN P. — Chief Financial Officer | Grant/award (A): 49,038 (derivative) | EDGAR |
| 2024-04-02 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Grant/award (A): 129,998 (derivative) | EDGAR |
| 2023-12-15 | 4 | Deliargyris Efthymios — Chief Medical Officer | Purchase (P): 22,557 @ $1.33 · Purchase (P): 7,894 (derivative) | EDGAR |
| 2023-12-15 | 4 | Capponi Vincent — President & COO | Purchase (P): 18,797 @ $1.33 · Purchase (P): 6,578 (derivative) | EDGAR |
| 2023-12-15 | 4 | BATOR MICHAEL G. — Director | Purchase (P): 37,594 @ $1.33 · Purchase (P): 13,157 (derivative) | EDGAR |
| 2023-12-15 | 4 | Jones Edward Raymond — Director | Purchase (P): 7,519 @ $1.33 · Purchase (P): 2,631 (derivative) | EDGAR |
| 2023-12-15 | 4 | BLOCH KATHLEEN P. — Chief Financial Officer | Purchase (P): 37,594 @ $1.33 · Purchase (P): 13,157 (derivative) | EDGAR |
| 2023-12-15 | 4 | Kim Jiny — Director | Purchase (P): 7,519 @ $1.33 · Purchase (P): 2,631 (derivative) | EDGAR |
| 2023-12-15 | 4 | Chan Phillip P. — Chief Executive Officer, Director | Purchase (P): 75,188 @ $1.33 · Purchase (P): 26,315 (derivative) | EDGAR |
Recent 8-K events — Cytosorbents Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-25 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-03-25 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CTSO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →